King Luther Capital Management Corp reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 14.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,988 shares of the medical research company’s stock after selling 15,965 shares during the period. King Luther Capital Management Corp owned about 0.21% of Charles River Laboratories International worth $9,911,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in CRL. BlackRock Inc. grew its position in shares of Charles River Laboratories International by 12,573.1% during the 1st quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock valued at $345,915,000 after acquiring an additional 3,815,298 shares during the period. FMR LLC grew its position in shares of Charles River Laboratories International by 39.7% during the 1st quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after acquiring an additional 707,612 shares during the period. Ariel Investments LLC grew its position in shares of Charles River Laboratories International by 30.7% during the 1st quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after acquiring an additional 483,564 shares during the period. MARSHALL WACE ASIA Ltd bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $39,355,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $39,355,000. 95.82% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/king-luther-capital-management-corp-trims-stake-in-charles-river-laboratories-international-inc-crl/1563917.html.

A number of research analysts have recently weighed in on the stock. Jefferies Group LLC reissued a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a research report on Tuesday. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Zacks Investment Research downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Barclays PLC reissued a “hold” rating and set a $102.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Charles River Laboratories International currently has an average rating of “Buy” and an average price target of $98.55.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) traded down 0.62% during mid-day trading on Friday, hitting $105.65. 76,709 shares of the company were exchanged. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $109.59. The company has a market capitalization of $5.03 billion, a P/E ratio of 27.84 and a beta of 0.99. The company has a 50 day moving average of $102.79 and a 200 day moving average of $95.17.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.20 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current year.

In other Charles River Laboratories International news, Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the transaction, the chairman now directly owns 361,178 shares in the company, valued at $36,117,800. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Davide Molho sold 10,948 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,094,800.00. Following the completion of the transaction, the insider now owns 27,497 shares of the company’s stock, valued at $2,749,700. The disclosure for this sale can be found here. Insiders have sold 79,982 shares of company stock valued at $7,951,868 over the last 90 days. 2.20% of the stock is currently owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.